Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial Meeting Abstract
| Authors: | Shanafelt, T. D.; Wang, V.; Kay, N. E.; Hanson, C. A.; O'Brien, S. M.; Barrientos, J. C.; Jelinek, D. F.; Braggio, E.; Leis, J. F.; Zhang, C. C.; Coutre, S.; Barr, P. M.; Cashen, A. F.; Mato, A. R.; Singh, A.; Mullane, M. P.; Little, R. F.; Erba, H. P.; Stone, R. M.; Litzow, M.; Tallman, M. S. |
| Abstract Title: | Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial |
| Meeting Title: | 61st Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 134 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Dec 7-10 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2019-11-13 |
| Start Page: | 33 |
| Language: | English |
| ACCESSION: | WOS:000518218500240 |
| DOI: | 10.1182/blood-2019-126824 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 642 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
